Pfizer Limited

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022-04 to 2023-03🗂️ Report periods on file: 2022-04 to 2023-03, 2018-04 to 2019-03

In its 2022-04 to 2023-03 reporting, Pfizer Limited disclosed greenhouse gas emissions of 3.4K tons/year (Scope 1 and 2). By scope: Scope 1: 63 tCO2e/year; Scope 2: 3.7K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
3.4K tons/year (Scope 1 and 2)
2022-04 to 2023-03
⚡
Renewable Energy
13%
of total energy
💧
Water Usage
35.3K kilolitres/year
2022-04 to 2023-03
♻️
Waste
166.90 metric tons/year
2022-04 to 2023-03
⚙️
Energy Use
662 MWh/year (renewable)
2022-04 to 2023-03

📊 Emissions by Scope (2022-04 to 2023-03)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).63 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.3.7K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2022-04 to 2023-033.4K tons/year (Scope 1 and 2)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

📅 Medium-term

  • Increase women representation in field force to 15%.

🔭 Long-term

  • Achieve Net-Zero emissions by 2040 (aligned with Pfizer Inc.'s goal).

🌱 ESG Focus Areas

Environmental SustainabilityDiversity, Equity & InclusionEthical OperationsAccess to MedicinesAntimicrobial Resistance

⚠️ Challenges & Risks +

  • Loss of exclusivity for key brands Eliquis and Zavicefta.
  • Revision of the National List of Essential Medicines (NLEM-2022) and consequent expansion of drugs under price controls.
  • Transition to a new Go-To-Market model.
  • Impending generic competition.

📋 Report Information

Reporting Period: 2022-04 to 2023-03